Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | VNN1 | O95497 | 13/20 | 0.59 |
| ▸ | ECE1 | P42892 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pantothenic Acid SCHEMBL5310119 | 1.00 | PTGS1 (0.65) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid, Racemic SCHEMBL27275744 | 1.00 | PTGS1 (0.65) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL2455676 | 1.00 | PTGS1 (0.65) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid, Racemic SCHEMBL28147773 | 1.00 | PTGS1 (0.65) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL34429 | 1.00 | PTGS1 (0.65) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid, Racemic SCHEMBL20592074 | 1.00 | PTGS1 (0.65) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL8044581 | 0.98 | PTGS1 (0.63) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL27652419 | 0.98 | PTGS1 (0.63) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL7084079 | 0.98 | PTGS1 (0.63) | PTGS1KCNH2VNN1ECE1 | |
| Pantothenic Acid SCHEMBL11749656 | 0.98 | PTGS1 (0.63) | PTGS1KCNH2VNN1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110287061-A1 | Dietary composition and method for promoting healthy hair growth and melanogenesis | BEGGAN CATHY (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110275708-A1 | POLYCYCLIC COMPOUNDS AND METHODS RELATED THERETO | CORNELL UNIVERSITY (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275708-A1 | POLYCYCLIC COMPOUNDS AND METHODS RELATED THERETO | PKD1, THPO, CCNO | PTGS1 34/4885KCNH2 3901/4885VNN1 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.